Comparative Pharmacology
Head-to-head clinical analysis: TEVETEN HCT versus VALSARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEVETEN HCT versus VALSARTAN AND HYDROCHLOROTHIAZIDE.
TEVETEN HCT vs VALSARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby antagonizing angiotensin II-induced vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
Oral, one tablet once daily. Starting dose: 160/12.5 mg or 80/12.5 mg. Titrate to 160/25 mg or 320/12.5 mg-320/25 mg based on response. Max: 320/25 mg/day.
None Documented
None Documented
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Valsartan: Terminal half-life ~6 hours; Hydrochlorothiazide: Terminal half-life ~6-15 hours (prolonged in renal impairment).
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Valsartan: 83% eliminated via feces (biliary), 13% via urine; Hydrochlorothiazide: ≥95% eliminated unchanged via urine.
Category C
Category D/X
ARB + Thiazide Diuretic Combination
ARB